TrialOrphanet journal of rare diseases2025

Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study.

Antonis Kattamis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.